Suscribirse

Integrating transcriptome and metabolomics analyses of hepatocellular carcinoma to discover novel biomarkers and drug targets - 14/02/25

Doi : 10.1016/j.clinre.2025.102546 
Ting Yang, Si-Yu Wang
 Clinical Laboratory, Zhongshan Hospital, School of Medicine, Xiamen University, 201-209 Hubin South Road, Xiamen, Fujian Province, 361014, China 

Corresponding author at: Zhongshan Hospital, School of Medicine, Xiamen University, 201-209 Hubin South Road, Xiamen, Fujian Province, 361014, China.Zhongshan HospitalSchool of MedicineXiamen University201-209 Hubin South RoadXiamenFujian Province361014China

Highlights

Metabolomics analysis found significant reductions in D-Mannose in HCC tissues.
DiAcSpm is highly up-regulated in HCC samples, which is similar to other cancers.
Reduction of L-Glutamine found indicated increased consumption of glutamate.
MAGEB2 up-regulation was observed in HCC for the first time.

El texto completo de este artículo está disponible en PDF.

Abstract

Background

Hepatocellular carcinoma (HCC) ranks sixth in incidence and third in mortality among all cancers. Chronic infection by hepatitis B and C viruses are the predominant risk factors for HCC, but other factors related to metabolic disorders including diabetes and obesity are also involved.

Methods

Ten male HCC patients with chronic HBV infection were included in this study. Primary HCC tissues were obtained from all study participants following liver resection. Normal tissues that were simultaneously collected served as the controls and were defined as tissue at least 5 cm from the tumor edge. Tissues were subjected to untargeted metabolomics and transcriptome analyses.

Results

We identified 31 and 41 differentially expressed metabolites (DEMs) in positive and negative ion modes, respectively. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that 15 DEMs were enriched in ABC transporters, nine in purine metabolism, eight in central carbon metabolism in cancer, and seven in biosynthesis of amino acids. Regarding the transcriptome analysis, 1,224 significantly up-regulated and 887 down-regulated RNAs were found. KEGG pathway analysis revealed that the most significantly enriched pathways were metabolic pathways. Integrated analysis showed seven pathways that were highly activated in HCC tissues including PI3K/Akt, ABC transporters, caffeine metabolism, carbon metabolism, biosynthesis of amino acids, arginine biosynthesis, alanine, aspartate, and glutamate metabolism.

Conclusion

Some DEMs could be biomarkers or therapeutic targets for HCC. Moreover, we found that MAGEB2 was significantly elevated in HCC tissues for the first time, and its association with HCC needs to be explored by functional studies.

El texto completo de este artículo está disponible en PDF.

Keywords : Hepatocellular carcinoma, Untargeted metabolomics, Transcriptome analysis, Liver tissues, Integrated analysis


Esquema


© 2025  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 49 - N° 4

Artículo 102546- avril 2025 Regresar al número
Artículo precedente Artículo precedente
  • Advancements of direct oral anticoagulants in cirrhotic individuals with portal vein thrombosis
  • Zhiqian Liu, Xiying Yang, Haitao Jiang, Rui Xie, Hong Wang
| Artículo siguiente Artículo siguiente
  • Suboptimal use of inpatient palliative care consultation in alcoholic hepatitis hospitalizations may lead to higher readmissions
  • Ali Jaan, Syeda Shahnoor, Abdul Moiz Khan, Umer Farooq, Qurat Ul Ain Muhammad, Kamran Qureshi

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.